DV
Dividend Vision

XENE — Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. (XENE)

Total return is 493.8% over the past 11.8 years, 126.7 points ahead of SPY at 367.1%. Its deepest 1-year drawdown was 18.4%.

Xenon Pharmaceuticals Inc. is a healthcare equity holding that focuses on pharmaceutical development and commercialization rather than functioning as a diversified ETF. As a single-stock investment, it does not have a distribution rate or yield profile, nor does it generate regular dividend distributions. This equity holding appeals to investors seeking exposure to the pharmaceutical sector through direct company stock ownership rather than those pursuing a dividend income strategy.

XENE key facts

Asset type
Stock
Asset class
Equity
Inception date
11/05/2014
Distribution frequency
None
Last close
$62.35
Market cap
$6,027,097,088
Average volume
913600.0
Beta
0.627
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.70